Abstract:Background Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension. Methods In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test. Results Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20±3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87±3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (±standard deviation) in the bimatoprost/timolol fixed combination group was (−9.38±4.66) mmHg and it was (−8.93±4.25) mmHg in the concurrent group (P <0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: −1.68, 0.57, P=0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P >0.05). Conclusions Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.

Clinical Investigation:The Intraocular Pressure-lowering Efficacy and Safety of Brinzolamide Combined with Betaxolol

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

Safety and Efficacy of Bimatoprost/timolol Fixed Combination in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Efficacy and safety of intravenous injection of lidocaine in the treatment of acute primary angle-closure glaucoma: a pilot study

Efficacy of brinzolamide in the initial management of acute primary angle closure: A randomized controlled trial

[The Ocular Hypotensive Effect and Safety of 0.2% Brimonidine].

Brinzolamide plus brimonidine for the treatment of glaucoma: an update

Intraocular pressure-reducing effects of latanoprost versus timolol in chinese patients with chronic angle-closure glaucoma.

Timolol,brinzolamide and Travoprost in Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension

A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.

Intraocular Pressure-Lowering Effects of Commonly Used Fixed-Combination Drugs with Timolol: A Systematic Review and Meta-Analysis

Fixed-combination Treatments for Intraocular Hypertension in Chinese Patients – Focus on Bimatoprost-Timolol

Liposomes As A Novel Ocular Delivery System for Brinzolamide: in Vitro and in Vivo Studies

A clinical multicenter comparative study of domestic and imported brimonidine in 139 patients

Ophthalmic Delivery of Brinzolamide by Liquid Crystalline Nanoparticles: In Vitro and In Vivo Evaluation

A Population-Based Assessment of 24-Hour Intraocular Pressure among Subjects with Primary Open-Angle Glaucoma: the Handan Eye Study

A 12-Week, Double-Masked, Parallel-Group Study of the Safety and Efficacy of Travoprost 0.004% Compared with Pilocarpine 1% in Chinese Patients with Primary Angle-Closure and Primary Angle-Closure Glaucoma

Sustained release of brimonidine from conjunctival sac insert to reduce intraocular pressure for glaucoma treatment

Influence of benzalkonium chloride in anti-glaucoma medications on intraocular pressure and ocular surface: a Meta-analysis

Clinical studies of D-timolol vs L-timolol